Does esaxerenone reduce nighttime home blood pressure in patients with uncontrolled nocturnal hypertension on ARB or CCB therapy?
101 patients with uncontrolled nocturnal hypertension being treated with an angiotensin receptor blocker (ARB) or calcium-channel blocker (CCB)
Esaxerenone added to background ARB or CCB therapy for 12 weeks
Change in nighttime home systolic/diastolic blood pressure from baseline to end of treatment (12 weeks) measured by brachial and wrist devicessurrogate
Esaxerenone effectively lowers nighttime home blood pressure and improves markers of organ damage in patients with nocturnal hypertension uncontrolled by ARBs or CCBs, though serum potassium requires monitoring.
There is limited evidence on the blood pressure (BP)-lowering effect of esaxerenone on home BP, including nighttime BP. Using two newly developed nocturnal home BP monitoring devices (brachial and wrist), this multicenter, open-label, prospective study investigated the nighttime home BP-lowering effect of esaxerenone in patients with uncontrolled nocturnal hypertension being treated with an angiotensin receptor blocker (ARB) or calcium-channel blocker (CCB). In total, 101 patients were enrolled. During the 12-week study period, change in nighttime home systolic/diastolic BP from baseline to end of treatment measured by the brachial device was -12.9/-5.4 mmHg in the total population and -16.2/-6.6 and -10.0/-4.4 mmHg in the ARB and CCB subcohorts, respectively (all p < 0.001). For the wrist device, the change was -11.7/-5.4 mmHg in the total population and -14.6/-6.2 and -8.3/-4.5 mmHg in each subcohort, respectively (all p < 0.001). Similar significant reductions were shown for morning and bedtime home BP and office BP. Urinary albumin-to-creatinine ratio, N-terminal pro-brain natriuretic peptide, and cardio-ankle vascular index improved in the total population and each subcohort. Incidences of treatment-emergent adverse events (TEAEs) and drug-related TEAEs were 38.6% and 16.8%, respectively; most were mild or moderate. The most frequent drug-related TEAEs were associated with serum potassium elevation (hyperkalemia, 9.9%; blood potassium increased, 3.0%); however, no new safety concerns were raised. Esaxerenone was effective in lowering nighttime home BP as well as morning and bedtime home BP and office BP, safe, and showed organ-protective effects in patients with uncontrolled nocturnal hypertension. Caution is warranted regarding elevated serum potassium levels. This study investigated the effect of esaxerenone on nighttime home BP and organ damage (UACR and NT-proBNP) in patients with uncontrolled nocturnal hypertension despite treatment with an ARB or CCB. Our results show that safe 24-h BP control and organ protection are possible with esaxerenone.
Building similarity graph...
Analyzing shared references across papers
Loading...
Kario et al. (Fri,) studied this question.
synapsesocial.com/papers/69d57684c23ff40c2825deff — DOI: https://doi.org/10.1038/s41440-023-01292-0
Kazuomi Kario
Preventive Cardiology
Masafumi Nishizawa
Sapporo Minami Hospital
Mitsutoshi Kato
Hypertension Research
Jichi Medical University
Daiichi-Sankyo (Japan)
Hiroshima City Asa Citizens Hospital
Building similarity graph...
Analyzing shared references across papers
Loading...
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: